Upload
others
View
17
Download
0
Embed Size (px)
Citation preview
`
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Singapore 26 – 28 September 2019
TABLE OF CONTENTS
COURSE INFORMATION ................................................................................................................. 1
FACULTY ........................................................................................................................................... 3
FLOOR PLAN ................................................................................................................................... 14
PROGRAMME .................................................................................................................................. 15
LECTURE ABSTRACTS.................................................................................................................. 18
SESSION 1: THE EPIDEMIOLOGY OF TB ............................................................................... 18
SESSION 2: PATHOLOGY OF TUBERCULOSIS ..................................................................... 20
SESSION 3: DIAGNOSING TUBERCULOSIS ........................................................................... 21
SESSION 4: TREATING TB AND DELIVERING CARE ......................................................... 23
SESSION 5: UPDATE ON THE CUTTING EDGE OF TB SCIENCE ....................................... 25
SESSION 6: COMPLEX PATIENTS: CASE-BASED DISCUSSIONS ...................................... 26
SESSION 8: NON-TUBERCULOUS MYCOBACTERIA........................................................... 27
POSTER ABSTRACTS ..................................................................................................................... 28
ACKNOWLEDGEMENTS............................................................................................................... 37
1
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
COURSE INFORMATION
COURSE DIRECTORS
• Jon S Friedland, London, United Kingdom
• Delia Goletti, Rome, Italy
• David Lye, Singapore
• Catherine Ong, Singapore
• Paul Tambyah, Singapore
COURSE VENUE
National University of Singapore
Yong Loo Lin School of Medicine
Clinical Research Centre Auditorium
MD11, 10 Medical Drive
Singapore 117597
WIFI AND LOGIN DETAILS
WIFI SSID: NUS-GUEST WIFI
WIFI PIN: UORS4V
PROGRAMME BOOKLET
There are 2 versions of programme booklet. A hardcopy programme booklet, distributed upon
registration, will contain only faculty listing and the programme. The E-copy of the programme
booklet will contain Faculty Biographies, Lecture Abstracts and Poster Abstracts. This
can be downloaded from the official website at https://escmid-sids.wizlink.com.sg.
CME ACCREDITATION
This course has been granted 11 European CME credits (ECMEC®s) by the European
Accreditation Council for Continuing Medical Education (EACCME®) and 8 CME credit points by
the Singapore Medical Council.
CERTIFICATE OF ATTENDANCE
The Certificate of Attendance will be issued on Saturday, 28th September 2019. Kindly collect at
the registration counter when you sign your attendance for the day.
For participants who signed up for single day programme, kindly collect your certificate of
attendance at the end of the day, at the registration counter.
POSTER PRESENTATION
Each presenter will be allocated a poster board (one side only) with an area of 1m x 2m. Each poster
board will be marked with a poster panel number. Poster should be set up on Thursday, 26
September 2019 between 1230 – 1300 hours and removed on Saturday, 28th September 2019 after
1030 hours. Poster judging will be on Friday, 27th September 2019, from 1130 – 1230 hours and
prizes will be awarded on Saturday, 28th September 2019.
2
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
FACULTY GROUP PHOTOGRAPH
All faculty kindly assemble on stage on Friday, 27th September at 10.00am, just before the morning
tea break.
FACULTY DINNER (by invitation)
Faculty members who require transport to the Dinner Venue, please inform the Course Secretariat
and assemble at the Foyer on Friday, 27th September by 1800 hours.
PERSONAL DATA
Participants should be aware that the organisers through others on behalf of organisers and third
parties, may be taking photographs and videos during the Postgraduate Course. Organisers may use
such photos in marketing materials, publications or media including social media, and we may
identify participants by name.
LOST AND FOUND
For lost and found items, please approach the Registration Counter.
LIABILITY
The Organisers are not liable for any personal accidents, illnesses, loss or damage to private
properties of delegates during the Course. Delegates are advised to make their own arrangements
with respect to personal insurance.
DISCLAIMER
Whilst every attempt will be made to ensure that all aspects of the Course will take place as
scheduled, the Organising Committee reserves the right to make appropriate changes should the
need arises with or without prior notice.
3
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
FACULTY
Assoc. Prof. Sylvie ALONSO
Associate Professor
Department of Microbiology and Immunology
National University of Singapore
Singapore
Associate Professor Alonso obtained her PhD degree in Microbiology and Molecular Biology from
the University Claude Bernard Lyon I (France) in 1998. She subsequently moved to Pasteur
Institute of Lille (France) for a 4-year post-doctoral training where she developed bacterial vaccine
delivery systems. Associate Profesor Alonso then spent 2 years at Cornell University (NY, USA) as
a Research Fellow where she worked on Tuberculosis. In 2004, she was awarded the Lee Kuan
Yew post-doctoral fellowship and joined the Department of Microbiology at NUS. She was
recruited as an Assistant Professor in 2007 and promoted to Associate Professor with tenure in 2013.
Assoc. Prof. Sophia ARCHULETA Head & Senior Consultant, Division of Infectious Diseases
University Medicine Cluster
National University Hospital
Director, National HIV Programme
National Centre for Infectious Diseases
Singapore
Associate Professor Sophia Archuleta is Head of the Division of Infectious Diseases at the National
University Hospital, and Director of the National HIV Programme, National Centre for Infectious
Diseases, Singapore. She is also a clinician educator and serves on the faculty of the National
University Health System Infectious Diseases Senior Residency Programme. Her clinical expertise,
and primary interest, is in the care of people living with HIV and its associated conditions.
Associate Professor Archuleta received her Bachelor of Science from Yale University in 1994 and
her M.D. from Albert Einstein College of Medicine in 1998. She completed her internal medicine
and infectious disease training at Mount Sinai Medical Center in New York and is board certified in
internal medicine and infectious diseases. In 2003, she joined the faculty of the Division of
International Medicine and Infectious Diseases at Weill Medical College of Cornell University
where she focused on HIV medicine and postgraduate education. A/Prof Archuleta joined the
Division of Infectious Diseases of the National University Hospital in Singapore in 2008 where she
established and led the HIV Programme until 2017. She was appointed Director of the National
HIV Programme, National Centre for Infectious Diseases in 2018. She is an Associate Professor of
Medicine at the Yong Loo Lin School of Medicine of the National University of Singapore, and
serves in various educational leadership roles and national committees on graduate medical
education. She is active in teaching learners across health professions and the entire medical
education continuum.
4
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Prof. Emmanuelle CAMBAU
Professor in Bacteriology-Virology-Hygiène
Medical School, University Paris Diderot
Head, Bacteriology laboratory
Lariboisiere Hospital, Hopitaux Universitaires Saint Louis-Lariboisière
Assistance Publique-Hôpitaux de Paris
Paris, France
Professor Cambau is a Professor in Bacteriology-Virology-Hygiène with the Medical School -
University Paris Diderot. She is also the Head of the Bacteriology Laboratory at Lariboisiere
Hospital, Hopitaux Universitaires Saint Louis-Lariboisière, Assistance Publique-Hôpitaux de Paris,
since 2010 and is a Member of the research team IAME UMR 1137 in Inserm-University Paris
Diderot
Professor Cambau obtained her Master’s Degree in Pharmacology from the University Paris 7 in
1989 and continued to pursue her Medical Doctor (M.D.) degree in Medical Biology from
University Paris 7 in 1991. In 1995, she received her Ph.D. degree in Microbiology and in 2001 her
Research Director Degree, both from the University Paris 5.
Professor Cambau has been the Associate Director of the French National Reference Center for
Mycobacteria since 2006. She is also a Member of the European network of national reference
laboratories for tuberculosis (ERLnet-TB) granted by the ECDC since 2010. She has been
appointed an Expert by the European Medical Agency, since 2011, and WHO network for
surveillance of resistance in leprosy, since 2008. She is also member of the WHO Technical
advisory group for Global Leprosy Program and has been a Member of the Executive Committee of
the European society for clinical microbiology and infectious diseases (ESCMID) since May 2018.
Professor Cambau was the Chair of the ESCMID Study group on mycobacterial infections
(ESGMYC) from 2011 to 2016 and Chair of the EUCAST subcommittee for antimycobacterial
susceptibility testing since 2016. She has published more than 230 papers, 170 communications
and 130 invitations for conferences.
Assoc. Prof. Cynthia CHEE
Director, Singapore TB Elimination Programme
National Centre for Infectious Disease
Director, Tuberculosis Control Unit
Tan Tock Seng Hospital
Singapore
Associate Professor Cynthia Chee is the Director of the Singapore TB Elimination Programme,
National Centre for Infectious Disease, and Director of the TB Control Unit, Tan Tock Seng
Hospital, Singapore. She obtained her medical degree from the National University of Singapore.
She underwent post graduate training in internal medicine, followed by advanced specialty training
in adult respiratory medicine. She has been working in TB control in Singapore since 1996 and was
involved in the implementation of the initiatives of the Singapore TB Elimination Programme since
its launch in 1997. Her research interests and publications pertain to the clinical and public health
aspects of TB.
5
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Assoc. Prof. Alex COOK Associate Professor
Biostatistics and Modelling Domain
Vice Dean (Research) & Domain Leader (Biostatistics & Modelling)
Saw Swee Hock School of Public Health
National University of Singapore
Associate Professor
Department of Statistics and Applied Probability
National University of Singapore
Associate Professor
Program in Health Services and Systems Research
Duke-NUS Graduate Medical School Singapore
Singapore
Associate Professor Alex Cook is an Associate Professor in the Saw Swee Hock School of Public
Health (SSHSPH) at the National University of Singapore (NUS), where he is also the Vice Dean of
Research and the Domain Leader of the Biostatistics and Modelling Domain. He also holds joint
appointments at the Duke-NUS Medical School Singapore, at the Department of Statistics and
Applied Probability, NUS. He works on infectious disease modelling and statistics, including
dengue, influenza and other respiratory pathogens, and on population modelling to assess the effect
of evolving demographics on non-communicable diseases such as diabetes.
Prof. Jon S FRIEDLAND Deputy Principal (Research & Enterprise)
St George’s, University of London
London, UK
Professor Jon Friedland is Deputy Principal (Research & Enterprise) at St George’s, University of
London having been Hammersmith Campus Director and Head of Infectious Diseases and
Immunity at Imperial College London. He is an honorary consultant in Infectious Diseases at St
George’s Hospital University NHS Trust.
His major research interests are in development of host mediated therapies targeting innate immune
responses in tuberculosis and in migrant health. He has published over 230 peer reviewed papers,
invited editorials and reviews, and edited 3 books.
Jon Friedland was awarded the Royal College of Physicians Weber-Parkes Prize Medal for research
in tuberculosis in 2005 and was elected Fellow of the UK Academy of Medical Sciences in 2008.
He was elected President of the British Infection Society (2007-09). He was elected Fellow of the
Royal College of Physicians of Ireland in 2010. In 2017, he was awarded an inaugural Fellowship
of the European Society of Clinical Microbiology and Infectious Diseases. He is currently a
Commissioner on the UK Commission for Human Medicines and Chair of the MHRA Expert
Advisory Group on Infection. He has previously served on the Joint Committee on Vaccination and
Immunisation and The Chief Medical Officers National Expert Panel on New and Emerging
Infections as well as on many grants committees including for the Medical Research Council (UK)
and The Wellcome Trust.
6
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Prof. Delia GOLETTI Infectious Diseases Specialist
Head, Translational Research Unit
Department of Epidemiology and Preclinical Research
National Institute for Infectious Diseases
Rome, Italy
Professor Delia Goletti is an Infectious Diseases Specialist, responsible of the Translational
Research Unit at the National Institute for Infectious Diseases in Rome, Italy. She has clinical
duties in the Lung Infectious Diseases outpatient clinic twice a week. Her research focus is on
tuberculosis immune pathogenesis, tuberculosis immunodiagnostic tests, biomarkers, autophagy,
impact of helminth infection on HIV and tuberculosis disease, impact of immune-suppressive
therapy on infectious diseases. She also works on the immune-pathogenesis of echinococcosis.
Professor Goletti is the chair of the ESCMYC group (working on Mycobacteria) at ESCMID and
she has ongoing collaborations worldwide (India, Africa, Europe, United States) on the translational
aspects of immune assays for tuberculosis. She collaborates with the World Health Organization
(WHO) and European Respiratory Society (ERS) on tuberculosis elimination and advocacy, with
the New Diagnostics Working Group Task Force on tests for progression of latent infection to
active disease supported by WHO and FIND
She is currently the academic editor of several journals including Journal of Infection, BMC
Infectious Diseases, PLoS ONE. She is also the co-chair of the group working on conventional T
cells within the “Collaboration for TB Vaccine Discovery” (CTVD) supported by the Bill and
Melissa Gates Foundation. She is present in the list of the top Italian scientists from 2014. She
publishes many papers with H index: Scopus 49; Web of Science: 47; Google Scholar 56.
Assoc. Prof. Li Yang HSU Head, Infectious Diseases Programme
Associate Professor
Saw Swee Hock School of Public Health
Yong Loo Lin School of Medicine
National University of Singapore
Head and Senior Consultant
Department of Infectious Diseases, Tan Tock Seng Hospital
Deputy Clinical Director, Communicable Diseases Centre
Ministry of Health, Singapore
Associate Professor Li Yang Hsu is an infectious diseases physician who has spent the past decade
researching and treating patients with antibiotic-resistant bacterial and invasive fungal infections.
He is currently Clinical Director of the National Centre for Infectious Diseases and Programme
Leader of the Infectious Diseases Programme at the Saw Swee Hock School of Public Health. He
was formerly the Director of the Singapore Infectious Diseases Initiative, which was established to
spur collaborative biomedical and clinical research in infectious diseases.
Associate Professor Hsu has served in several Ministry of Health committees, in particular co-
chairing the RIE2020 infectious diseases workgroup, promoting the causes of antimicrobial
stewardship, better control of antimicrobial resistance (leading to the launch of Singapore’s
National Strategic Action Plan on Antimicrobial Resistance in November 2017), as well as
7
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
tuberculosis. He continues to work with MOH on the part-time professional scheme. He has also
served as a technical advisor on surveillance of antimicrobial resistance to the western pacific
regional office of the World Health Organization.
Associate Professor Hsu was the founding director of the Centre for Infectious Disease & Research
(CIDER) at the Saw Swee Hock School of Public Health in 2012, and has briefly worked in the
private sector as an infectious disease physician, providing specialist services between 2014 and
2016.
Dr. Tauhidul ISLAM Coordinator, End TB and Leprosy Unit
Division of Programmes for Disease Control
Western Pacific Regional Office
World Health Organization
Manila, Philippines
Dr Tauhid Islam is leading End TB and Leprosy Unit of the Division of Disease Control in the
Western Pacific Regional Office of WHO. He is responsible for coordinating technical support,
monitoring the Regional TB situation and promoting innovative interventions through translation of
new policies into practice and through addressing system challenges. Dr Islam has over 15 years of
experience in TB control with experience at global, regional and national level. He has worked
closely with numerous stakeholders including Member States, civil society, as well as national and
international partners. He contributed to the development of WHO guidelines and policies on TB
and MDR-TB.
Prof. Yee-Sin LEO Director, Institute of Infectious Disease and Epidemiology
Clinical Director, Communicable Disease Centre
Senior Consultant
Tan Tock Seng Hospital
Singapore
Professor Yee-Sin Leo, an adult Infectious Disease specialist, is the Executive Director of the
National Centre of Infectious Diseases. She is known for leading her team battling through multiple
outbreaks in Singapore in recent decades. Her encounters include the Nipah outbreak in 1999,
SARS in 2003, pandemic influenza in 2009 and multiple surges of vector-borne diseases including
the recent zika outbreak in Singapore.
Her work won her many awards including the most prestigious Public Service Star in recognition of
her contributions during the SARS outbreak. Other awards include the Excellence Star Award in
2005, the Red Ribbon Award in 2014 and the National Healthcare Group (NHG) Distinguished
Senior Clinician Award in 2016.
Professor Leo is extremely active in academic advancement. Her key research interests are
emerging infectious diseases, dengue, and HIV. Her recent focus on point-of-care testing (POCT)
attests to her work in improving patient care and outbreak control. To date Professor Leo has
published more than 200 scientific papers and is highly sought after as an advisor and conference
speaker.
8
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Asst. Prof. Catherine ONG Principal Investigator
Department of Medicine, Yong Loo Lin School of Medicine
Institute for Health Innovation & Technology
National University of Singapore
Consultant, Division of Infectious Diseases
University Medicine Cluster, National University Hospital
Singapore
Assistant Professor Catherine Ong is Principal Investigator in the Department of Medicine (Yong
Loo Lin School of Medicine) and Institute for Health Innovation & Technology (iHealthtech) at the
National University of Singapore, Honorary Secretary of the Chapter of Infectious Disease
Physicians (Academy of Medicine, Singapore), Council Member of the College of Clinician-
Scientists and Vice-President of Society of Infectious Disease (Singapore). Her clinical interests are
in TB in immunocompromised hosts including people living with HIV and in the transplant setting.
Assistant Professor Ong joined the Division of Infectious Diseases at National University Hospital
in 2007 where she developed a passion for TB. She was awarded the competitive 2008 NRF-MOH
Healthcare Research Scholarship funded by the Singapore National Medical Research Council
(NMRC) and pursued full-time research on TB host immunopathology with Professor Jon Friedland
at Imperial College London which led to the conferment of her PhD in 2013. During her UK
research, she was awarded a Presidential Award prize at the American Society for Leukocyte
Biology, the Keystone Symposia Global Health Travel Award by Bill and Melinda Gates
Foundation and the International Investigator Award by the Infectious Diseases Society of America.
On return, she was awarded the Exxon-Mobil NUS Research Fellowship in 2014, the NUHS
Clinician-Scientist Programme 2014-15, the NMRC Transition Award in 2015, the NMRC
Clinician Scientist Award in 2018 and the Institut Merieux- Society of Infectious Disease
(Singapore) Young Investigator Award 2018. Her research interests are in TB host-pathogen
interactions, biomarker discovery and host-directed therapies.
Asst. Prof. Rick ONG
Assistant Professor
Saw Swee Hock School of Public Health
National University of Singapore
Singapore
Assistant Professor Rick Ong is a bioinformatician who combines computer science, statistics,
population genetics and genomics to develop and apply novel algorithms and software in the
research and analysis for molecular epidemiology, pathogenesis, tracking and control of outbreaks
in infectious diseases, including monitoring of antimicrobial resistance for public health
surveillance. He is currently an Assistant Professor with the Saw Swee Hock School of Public
Health at the National University of Singapore. He has a BEng (Computer Engineering), MSc
(Computer Science) and PhD from National University of Singapore and a Msc (Bioinformatics)
from Nanyang Technological University.
9
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Prof. Nick PATON Professor of Infectious Diseases
National University of Singapore
Senior Consultant, Division of Infectious Diseases
University Medicine Cluster
National University Hospital
Singapore
Prof Nicholas Paton trained in Medicine and Infectious Diseases in Cambridge, Sydney and London,
and in Epidemiology at the London School of Hygiene and Tropical Medicine. From 1997 to 2005,
he worked at Tan Tock Seng Hospital Singapore, serving terms as Head of Department of
Infectious Diseases and as Hospital Research Director. He then returned to the UK, to work in the
MRC Clinical Trials Unit (MRC CTU) leading large scale HIV treatment trials, such as PIVOT and
EARNEST (for which he is the Chief Investigator). He also worked with international research
networks such as INSIGHT and NEAT. In 2011, he accepted the Professor of Medicine position, in
the Department of Medicine at the National University of Singapore (NUS). At NUS, he is working
on a programme of international TB research, focused on developing novel endpoints for TB trials
and on clinical trials evaluating new TB drug combinations.
Assoc. Prof. Kevin PETHE Associate Professor of Infectious Disease
Principal Investigator
Microbiology and Systems Biology Laboratory
Lee Kong Chian School of Medicine
Nanyang Technological University
Singapore
Before joining the Nanyang Technological University, Associate Professor Kevin Pethe gained
expertise in Research & Development in the private sector as research investigator and project
manager at the Novartis Institute for Tropical Disease (Singapore) from 2004 to 2011. He then took
a position of principal investigator at Institut Pasteur Korea to pursue his interest on host-pathogen
interactions and chemical biology applied to tuberculosis and multidrug resistant bacteria. He
became head of the departments of disease biology & chemical genomics in 2013, and nominated
acting CEO of Institut Pasteur Korea the same year.
Kevin is interested in the pathogenesis of Mycobacterium tuberculosis, microbial bioenergetics, and
on strategies to discover novel antibacterial agents. Notably, he led interdisciplinary teams that
developed clinical-stage drug candidates for tuberculosis and related mycobacteria.
Kevin Pethe is teaching microbiology, antibiotic drug development, infectious diseases and
pharmacokinetics to undergraduate and graduate students in the Lee Kong Chian School of
Medicine, the College of Science, and the College of Engineering of the Nanyang Technological
University.
10
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Dr Zubaidah SAID Public health physician and Deputy Director
Communicable Diseases Division
Ministry of Health, Singapore
Zubaidah Said is a public health physician and Deputy Director at the Communicable Diseases
Division in the Ministry of Health, Singapore. Her areas of interest are in epidemiology, public
health policy and health economics.
Dr. Chew Swee SEOW
Senior Consultant Dermatologist
National Skin Centre
Singapore
Dr Seow Chew Swee is a Senior Consultant Dermatologist responsible for the treatment and
teaching of skin diseases in the Department.He is especially passionate about treatment common
skin conditions like eczema, acne, psoriasis, infections of the skin and pigment problems
and diseases of the hair and nail. His research interest centers on infection of the skin, including
Leprosy, and diseases peculiar to Asian population.
Dr Seow Chew Swee graduated from the University Malaya in Malaysia and subsequently obtained
the Master’s Degree in Medicine in Singapore. He proceeded with the training in Dermatology and
Medical Mycology at Institute of Dermatology, University of London in the United Kingdom. He is
Fellow of Asian Academy of Dermatology and Venereology (FAADV).
Adj Asst. Prof. Amit SINGHAL Adjunct Assistant Professor
Lee Kong Chian School of Medicine
Nanyang Technological University
Principal Investigator
Singapore Immunology Network
Agency for Science, Technology and Research
Singapore
Adjunct Assistant Professor Amit Singhal began his career in the field of infectious disease
immunology as a PhD fellow at All India institute of Medical Sciences, India. After doing
postdoctoral stints at Institute Pasteur and Novartis Institute for Tropical Disease he started his
group in SIgN in 2014. He is applying various basic and advanced approaches (at both population
and single cell level), to understand the mechanisms utilized by bacteria for evading host’s
immuno-metabolic circuits. The information gained from these experiments is being currently
exploited for designing clinically relevant biomarkers and host-directed therapeutic interventions.
He is also an Adjunct Assistant Professor (Honorary) at the Lee Kong Chian School of Medicine,
Nanyang Technological University, Singapore
11
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Dr. Li Hwei SNG Senior Consultant
Head, Central Tuberculosis Laboratory
Singapore General Hospital
Co-director
The Infectious Diseases Research Institute (IDRI)
Singapore
Dr Sng Li-Hwei is a pathologist specializing in medical microbiology, a Senior Consultant and the
Head of the Central Tuberculosis Laboratory (CTBL), Singapore General Hospital (SGH) since
2003. She graduated from the National University of Singapore, received microbiology training at
the SGH, Department of Pathology and the Cleveland Clinic Foundation, USA; and
Mycobacteriology specialist training at the Centers of Disease Control and Prevention, Atlanta,
USA.
She is actively involved in various workgroups for mycobacterial diagnosis and control. Her
interests involve novel diagnostic methods and the integration of advanced technology and testing
platforms in clinical diagnostic laboratories, antimicrobial resistance and epidemiological studies,
especially mycobacteria. The CTBL serves as the national reference laboratory for tuberculosis and
has collaboration with local and international scientists and researchers in developing TB
diagnostics, fingerprinting assays, and studies involving whole genome sequencing and
evolutionary biology.
Prof. Paul TAMBYAH Professor
Department of Medicine, Yong Loo Lin School of Medicine
National University Singapore
Senior Consultant
Division of Infectious Diseases, University Medicine Cluster
National University Hospital
Singapore
Paul Ananth Tambyah is currently Professor of Medicine at NUS and senior consultant Infectious
Diseases Physician at the National University Hospital and also head of the Infectious Diseases
Research Coordinating Office at the National Center for Infectious Diseases. He is also President of
the Asia Pacific Society of Clinical Microbiology and Infection. His research interests are in device
associated infection and emerging infectious diseases
12
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Prof. Guy THWAITES Director
Oxford University Clinical Research Unit
Wellcome Trust Major Overseas Programme
Vietnam
Professor of Infectious Diseases
University of Oxford
Honorary Consultant in Infectious Diseases and Clinical Microbiology
Guy’s and St. Thomas’ NHS Foundation trust
UK
Professor Thwaites qualified from Cambridge University and the United Medical and Dental
schools of Guy’s and St Thomas’ and trained in Infectious Diseases and Microbiology in Brighton,
the Oxford University Clinical Research Unit (OUCRU) in Vietnam, Imperial College London, and
the Hospital for Tropical Diseases in London. His research interests focus on the management of
severe bacterial infections, especially those involving the central nervous system. He has held
Wellcome Trust Training (2001-2004) and Intermediate (2006-2011) Fellowships, and was recently
awarded a Wellcome Trust Investigator Award (2016-2023) to further his research on tuberculosis
in Vietnam.
In 2013 he was appointed Director of the Oxford University Clinical Research Unit and Wellcome
Trust Major Overseas Programme in Viet Nam. He is responsible for the scientific strategy and day-
to-day management of the entire programme, which includes research units in Viet Nam, Nepal and
Indonesia.
Professor Thwaites has published more than 160 articles in international journals and has an H
index of 39 (Scopus)
Prof. Reinout van CREVEL Professor in Global Health and Infectious Diseases
Radboud University Medical Center
Nijmegen, The Netherlands
Professor Reinout van Crevel studied medicine in Amsterdam and now works as an internist-
infectious diseases specialist in Nijmegen, the Netherlands. His clinical work covers the full specter
of infectious diseases, including severe or treatment-refractory cases of tuberculosis and infections
caused by non-tuberculous mycobacteria. His research mainly focusses on TB, integrating patient
studies and laboratory sciences, and focussing on TB meningitis, TB and diabetes and M.
tuberculosis infection. He has a collaborated for 20 years with researchers in Indonesia, where he
has lived for 3 years, and currently has a part-time position at the Oxford Clinical Research Unit in
Jakarta.
13
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Assoc. Prof. Tsin Wen YEOAssociate Professor of Infectious Disease
Principal Investigator, Malaria, Tuberculosis and Global Health Laboratory
Lee Kong Chian School of Medicine
Nanyang Technological University
Singapore
Associate Professor Yeo is an Associate Professor at the Lee Kong Chian School of Medicine,
Nanyang Technological University. Associate Professor Yeo graduated from the National
University of Singapore, and went on to complete an internal medicine residency at the University
of Hawaii as well as an infectious disease fellowship at the University of Utah. He did his PhD at
the Menzies School of Health Research and University of Queensland on the treatment and
pathogenesis of severe malaria based in Indonesia Papua. Upon completion of his PhD, he worked
as a research fellow at the Menzies School of Health Research and as an infectious physician at
Royal Darwin Hospital in Australia. In 2016, he was awarded the Clinician-Scientist Award (CSA)
in the Investigator (INV) category from Singapore’s National Medical Research Council (NMRC).
Associate Professor Yeo’s research group at NTU’s Lee Kong Chian School of Medicine focuses
on clinical and epidemiological studies of malaria including the three species most prevalent in
South East Asia, namely Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi
14
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
FLOOR PLAN
Poster Area
Auditorium
Exh
ibit
ors
OFFICES
Mee
tin
g
Ro
om
Mee
tin
g
Ro
om
Mee
tin
g R
oo
m
Mee
tin
g R
oo
m
Store
Sym
po
siu
m
Ro
om
Med
ical
Stu
den
t
Lou
nge
Lift
s
Lifts
Sto
re
Mec
han
ical
Ro
om
Stairway
Ris
er
Entran
ce
Lobby
Registration
CAFE
15
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
PROGRAMME
Day 1: Thursday, 26th Sept 2019
Session 1: The Epidemiology of TB
Chair: Prof Jon FRIEDLAND
1300 – 1320 Registration
1320 – 1330 Opening Remarks
1330 – 1400 Epidemiology of TB in Singapore and TB
Control Efforts
Dr Zubaidah SAID (SG)
Communicable Disease Division,
Ministry of Health
1400 – 1430 The Global and Regional Experiences and the
End of TB Strategy
Dr Tauhidul ISLAM (PH)
World Health Organisation
1430 – 1500 TB and Migration Assoc Prof Alex COOK (SG)
Saw Swee Hock School of Public
Health, NUS
1500 – 1530 TB Biomarkers Prof Delia GOLETTI (IT)
ESGMYC Chair
1530 – 1600 Refreshment Break
Session 2: Pathology of Tuberculosis
Chair: Asst Prof Catherine Ong
1600 – 1640 Host Immune Defence in Tuberculosis, A
Clinical Perspective
Prof Reinout van CREVEL (NL)
Radboud University
1640 – 1720 Physiology and Pathology of TB Prof Jon FRIEDLAND (UK)
St George’s, University of London
1720 Question-Answer Session, Light Refreshments and Networking
End of Day 1
16
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Day 2: Friday 27th Sept 2019
Session 3: Diagnosing Tuberculosis
Chair: Assoc Prof Sophia ARCHULETA
0900 – 0930 Understanding the Use of Interferon Assays Prof Delia GOLETTI (IT)
ESGMYC Chair
0930 – 1000 The Role of the Microbiology Laboratory Prof Emmanuelle CAMBAU (FR)
ESCMID Council and Past
ESGMYC Chair
1000 – 1030 Refreshment break and Faculty Photo Taking
Session 4: Treating TB and Delivering Care (Part 1)
Chair: Assoc Prof Tsin Wen YEO
1030 – 1100 Whole Genome Sequencing in TB Assoc Prof Li Yang HSU (SG)
Asst Prof Rick ONG (SG)
Saw Swee Hock School of Public Health, NUS
1100 – 1130 Public Health and Social Aspects of TB
Management
Assoc Prof Alex COOK (SG)
Saw Swee Hock School of Public
Health, NUS
1130 – 1230 Lunch Break, Poster Judging
Session 4: Treating TB and Delivering Care (Part 2)
Chair: Prof Emmanuelle CAMBAU
1230 – 1300 Managing Drug-Resistant TB Assoc Prof Cynthia CHEE (SG)
TB Control Unit
1300 – 1330 Extra-Pulmonary TB Assoc Prof Tsin Wen YEO(SG)
Lee Kong Chian School of
Medicine, NTU
1330 – 1400 CNS-TB Prof Guy THWAITES (VN)
Oxford Clinical Research Unit
Session 5: Update on the Cutting Edge of TB Science
Chair: Assoc Prof Sylvie ALONSO
1400 – 1420 Clinical Trials in TB Prof Nick PATON (SG)
Yong Loo Lin School of
Medicine, NUS
1420 – 1440 Host-Directed Therapy in TB Adj Asst Prof Amit SINGHAL
(SG)
Singapore Immunology Network,
A*Star
1440 – 1500 New Kids on the Block Assoc Prof Kevin PETHE (SG)
Lee Kong Chian School of
Medicine, NTU
1500 – 1530 Refreshment Break
17
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Day 2: Friday 27th Sept 2019 (Cont’d)
Session 6: Complex Patients: Case-Based Discussions
Chair: Prof Delia GOLETTI
1530 – 1600 TB and HIV Prof Yee Sin LEO (SG)
National Center for Infectious
Diseases
1600 – 1630 TB and DM Prof Reinout van CREVEL (NL)
Radboud University
1630 – 1700 Managing TB in the Immunocompromised Asst Prof Catherine ONG (SG)
Yong Loo Lin School of
Medicine, NUS
1700 – 1730 Challenging TB Cases in Asia Prof Guy THWAITES (VN)
Oxford Clinical Research Unit
1900 – 2100 Faculty Dinner (by invitation)
End of Day 2
Day 3: Saturday 28th Sept 2019
Session 7: Debate
Chair: Asst Prof Catherine ONG
0900 – 1000 Topic: – The focus in TB must be on research in diagnostics and treatment, not
social aspects of the disease
Proposed by: Prof Paul TAMBYAH (SG)
Opposed by: Prof Jon FRIEDLAND (UK)
1000 – 1030 Refreshment Break
Session 8: Non-Tuberculous Mycobacteria
Chair: Prof Paul TAMBYAH
1030– 1100 Microbiological Diagnosis Prof Emmanuelle CAMBAU (FR)
ESCMID Council and Past
ESGMYG Chair
1100 – 1130 An update on the diagnosis and management of
non-tuberculous mycobacterial infections –
Perspectives from the Singapore Laboratory
Dr Li-Hwei SNG (SG)
Central TB Laboratory
1130 – 1200 Leprosy Dr Chew Swee SEOW (SG)
National Skin Centre
1200 – 1300 Closing Remarks, Poster Prize Presentation, Lunch and Future Planning
End of Course
18
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
LECTURE ABSTRACTS
SESSION1: THE EPIDEMIOLOGY OF TB
Epidemiology of TB in Singapore and TB Control Efforts
Dr Zubaidah SAID
TB in Singapore was prevalent in Singapore until 1970s, when it started to decline due to improved
hygiene and sanitation, and medical treatment. In 1997, the Singapore TB Elimination Program
(STEP), was set up to further reduce the TB incidence in Singapore. STEP runs the national
Directly Observed Treatment (DOT) program, and coordinates the treatment, investigation, and
contact tracing around active TB cases. This has led to a further reduction in TB incidence rates in
Singapore.
Singapore adopts a multipronged approach to reduce TB incidence rates. To further strengthen TB
control efforts, novel approaches are being explored, and this presentation will detail some of these
approaches.
The Global and Regional Experiences and the End of TB Strategy
Dr Tauhidul ISLAM
Worldwide, TB is one of the top ten causes of death and the leading cause from a single infectious
agent. In 2017, TB caused an estimated 1.6 million deaths, around 10 million people developed TB
disease which includes 1.0 million children. Drug-resistant TB continues to be a public health crisis.
More than half a million people developed TB that was resistant to rifampicin (RR-TB), the most
effective first-line drug. Burden of TB disease is still high, affecting all countries, all ages, men,
women and children. In the Western Pacific region, an estimated 1.8 million people developed TB
and also had estimated 114,231 incident multi-drug resistant (MDR) TB cases in 2017. There is
progress, but it is slow - not fast enough to reach End TB targets or make major headway in closing
persistent gaps. This Region is in the crossroad of old and new challenges. Old challenges include
missing TB cases, huge pool of latent TB infection, slow uptake of innovations and catastrophic
cost incurred by TB affected person and families. New Region specific emerging challenges include
rapid economic growth, urbanization and ageing of the population. Rapid economic growth quickly
changes the funding landscape and health financing modalities, flourishes private sectors. Rapid
urbanization makes interventions complex. TB in elderly requires more comprehensive package of
patient centred care including co-morbidity management. Policy - practise pathway remains a major
challenge – it takes a huge ‘time’ toll, sometime ‘pilot’ becomes the enemy of ‘scale-up’. In the
Western Pacific, WHO will address these issues in partnership with Member States by
operationalizing the strategic shifts by focusing on innovation, back casting, systems approach,
building solutions from the ground up, championing health, beyond the health sector, driving and
measuring country impact and strategic communications as a means to deliver on new ways of
working. The declaration of the first-ever United Nations High Level Meeting on TB created a
major momentum to reach all people by closing the gaps on TB diagnosis, treatment and prevention
and commit to decisive and accountable leadership.
19
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
TB and Migration
Assoc Prof Alex COOK
TB Biomarkers
Prof Delia GOLETTI
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is still an important global health
problem with 10 million cases worldwide estimated in 2017 by the World Health Organization
(WHO) and 1.7 million deaths. This number of deaths is unacceptably high because with prompt
diagnosis and appropriate treatment, almost all TB patients can be cured. Almost one-fourth of the
world’s population is latently infected with Mtb with a risk of progression to active disease of about
3-15% during their lifetimes. Being latent TB infection (LTBI) an important reservoir for TB
disease progression, an effectively elimination of TB epidemic is feasible only diagnosing and
treating LTBI.
Accurate and fast TB diagnosis can be difficult, due to several limitations in the currently available
diagnostic tests. In the case of pulmonary TB, sputum-based tests require a Mtb-positive sputum
even though many active TB patients, including HIV-coinfected individuals, diabetes patients and
children, often do not present with Mtb-positive sputum and thus cannot provide microbiologically
positive specimens. Moreover, in extra-pulmonary disease, sputum-based diagnostics are
inapplicable, and diagnosis relies on samples often collected by invasive procedures. For all of these
reasons, a sensitive and specific diagnostic tests for TB to rapidly identify—or rule out—the
presence of active disease is needed. The World Health Organization recently defined high-priority
target product profiles for TB diagnostics. These include a rapid non-sputum-based test for
detecting TB with the purpose of starting specific TB therapy on the same day. These tests need to
perform in endemic settings with limited laboratory facilities, at low cost, using easily accessible
non-sputum-based samples such as (finger prick) blood, urine or breath. Therefore, there is an
urgent need to search for biomarkers (BM) that could be used in such tests. Disease-related TB-BM
could find application in improved and fast clinical decision making, for example in developing
improved tests that more accurately and differentially diagnose TB disease. New promising
experimental tests will be discussed.
20
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
SESSION 2: PATHOLOGY OF TUBERCULOSIS
Host Immune Defence in Tuberculosis, A Clinical Perspective
Prof Reinout van CREVEL
Host immunity is critical for protection against Mycobacterium tuberculosis, and decreased host
immunity may lead to disseminated or severe manifestations of tuberculosis as well as infections
with non-tuberculous mycobacteria. The host inflammatory response may also lead to unwanted
tissue pathology, and thereby worsen patients’ clinical outcome. This discussion will discuss
clinical cases to provide practical guidance for diagnosis and management of host immune defects
and immunopathology associated with TB.
Physiology and Pathology of TB
Prof Jon FRIEDLAND
Tuberculosis still kills more people than any other single infection and the rise of drug resistance
necessitates a search for new approaches to treatment potentially harnessing the human immune
response to fight disease. Patients with tuberculosis (TB) are often characterized by having
extensive pathology most typically pulmonary cavitation. However, patients have also frequently
lost weight, have a fever and on blood gas analyses, are likely to be both hypoxic and acidotic
reflecting severe accompanying physiological changes. Tissue destruction in Tb is not primarily a
result of pathogen activity but due to the innate inflammatory immune response and in particular,
the destructive effect of enzymes, particularly the matrix metalloproteinase (MMPs) which are
unique in being able to destroy the triple helix of collagen.
In the talk, I shall review some recent work on the regulation of MMPs and the impact on tissue
damage in tuberculosis. I shall consider aspects of the influence of metabolic change, hypoxia and
acidosis on the regulation of MMPs and the inflammatory response in tuberculosis. I shall first
address the question of whether TB lesions are even hypoxic since current dogma is that the disease
location in the upper lowers of the lung reflects a predilection of the organism for an aerobic
environment. There are almost no data on the impact of acidosis on macrophage function even in
the absence of tuberculosis and so I shall examine both the impact of acidosis on macrophage
function before considering what happens in tuberculosis in the presence of acidosis. There will be
emphasis in the talk on what actually happens in the TB patient since understanding
pathophysiological change is key in considering the development of host directed therapies.
21
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
SESSION 3: DIAGNOSING TUBERCULOSIS
Understanding the Use of Interferon Assays
Prof Delia GOLETTI
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is still an important global health
problem with 10 million cases worldwide estimated in 2017 by the World Health Organization
(WHO). Almost one-fourth of the world’s population is latently infected with Mtb with a risk of
progression to active disease of about 3-15% during their lifetimes. Being latent TB infection (LTBI)
an important reservoir for TB disease progression, an effectively elimination of TB epidemic is
feasible only diagnosing and treating LTBI.
Currently, there are no gold standard tests for LTBI diagnosis. Tuberculin skin test (TST) and T-cell
interferon-γ release assays (IGRAs) are the routine tools used. TST is based on an immune reaction
to the intradermal injection of purified protein derivate of tuberculin, a mixture of antigens that,
however, is shared by Mtb and bacille Calmette–Guérin (BCG), as well as other mycobacteria,
affecting the test specificity.
To overcome this limitation, two IGRAs, Quantiferon®-TB Gold Plus (QFT) and T-Spot®.TB
(TSPOT), were developed. IGRAs measure the IFN-γ production to Mtb specific peptides (ESAT-6,
CFP-10) located in the region of difference (RD) 1 of Mtb and this leads to a higher specificity for
LTBI detection compared to TST. However, since both TST and IGRAs imply an immune reaction,
these tests have a suboptimal diagnostic accuracy in immunocompromised patients as well as in
children who have an immature immune system. Finally, TST and IGRAs do not differentiate
between active TB and LTBI, between active TB and cured TB, between recent and remote
infections. New promising experimental tests that may overcome these limitations are available and
will be discussed.
The Role of the Microbiology Laboratory
Prof Emmanuelle CAMBAU
Tuberculosis is due to the multiplication of bacteria speciated as Mycobacterium tuberculosis
complex, grouping different variants and lineages. The disease is mainly respiratory TB, which
accounts for 75% of cases and is highly contagious. Extra-respiratory TB may involve any organ
and lymphatic nodes since it resulted from the dissemination of the bacilli. The challenge of clinical
microbiology laboratories is first to make the diagnosis as early as possible to implement measures
to prevent air-borne transmission, and second to detect the multidrug resistant TB cases since these
patients will not be cured following the standard HRZE treatment. The detection of acid-fast bacilli
(AFB) on sputum smears using Ziehl-Neelsen staining under light microscopy remains a quick and
reliable test for the diagnosis of pulmonary TB and the cheapest. Staining with auramine with
reading using LED microscopy improves the detection and the easiness. About half of the
pulmonary TB cases are smear-positive, depending on the area. Cultures are difficult since they
require a decontamination step, which in theory is supposed to kill bacteria others than
mycobacteria while leaving alive the mycobacteria. Practically this is not that obvious and needs an
equilibrium between the two actions of kill and preserve, and needs good indicators. If culture in
liquid medium gives a positive signal earlier than solid medium, both are necessary to increase the
sensitivity of the culture, i.e. the positive diagnosis of smear-negative TB cases. Smear-positive
cases can be rapidly confirmed as TB cases by performing nucleic acid amplification tests (NAAT)
directly on specimen. NAAT can be also useful to diagnose a smear-negative TB case although it is
less sensitive than culture, and cost-effectiveness should be evaluated with regards to the area where
22
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
it is applied. It is now recommended for any person with high suspicion of TB. Susceptibility
testing is much more difficult for MTb than for other bacteria and requires laboratories with
expertise, safety rooms BSL3 and specific equipment. Different methods and many techniques are
available although they need to be validated with regards to the reference. EUCAST worked on a
reference protocol to be tested for new antituberculous drugs in order to homogenize the results
over the world. TB is developing in persons who have been infected in the previous years and these
persons may show interferon gamma response (IGRA) when their lymphocytes are stimulated with
specific antigens. All these diagnostic tools help in the management and prevention of TB
transmission, including whole genome sequencing for comparing isolates.
23
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
SESSION 4: TREATING TB AND DELIVERING CARE
Whole Genome Sequencing in TB
Assoc Prof Li Yang HSU & Asst Prof Rick ONG
The recent advancements in molecular sequencing technologies and bioinformatics have enabled
the high-throughput and cost-effective examination of the entire genetic composition of infectious
pathogenic microorganisms. By tracking the genomic variations in bacteria over their evolution
across time and space; correlating with phenotypes such as antimicrobial resistance will allow
greater resolution than current methods in investigation of disease outbreaks to determine their
spread and transmission. In this lecture, I will introduce the basic techniques and concepts to
sequencing technologies and bioinformatics approaches underlying the inference of antimicrobial
resistance for clinical treatment and disease transmission between individuals for public health
surveillance from Mycobacterium tuberculosis genomic data.
Public Health and Social Aspects of TB Management
Assoc Prof Alex COOK
Managing Drug-Resistant TB
Assoc Prof Cynthia CHEE
Multidrug resistant (MDR) and rifampicin resistant (RR) TB are difficult to treat and pose a
challenge to TB control efforts worldwide. Global programmatic treatment outcomes for MDR-TB
have been poor at around 50% with high defaulter rates due to second-line drug toxicity and
prolonged treatment duration.
The 2019 World Health Organization (WHO) MDR / RR TB treatment guidelines significantly
departs from previous editions in that the second-line drugs are re-grouped, and the injectable
agents (kanamycin and capreomycin) are no longer recommended. These guidelines strongly
recommend a later generation fluoroquinolone (levofloxacin or moxifloxacin), bedaquiline and
linezolid (Group A medications) to be included, with the addition of clofazimine and/or cycloserine
or terizidone (Group B medications) to form a regimen comprising at least 4 effective drugs in the
first 6 months, followed by at least 3 effective drugs for a total duration of 18-20 months. Group C
medications comprise all other medications which can be used, ranked by the relative balance of
benefit to harm, when a regimen cannot be composed with Group A and B agents. TB laboratories
will have to build capacity to provide appropriate drug susceptibility testing in response to these
latest guidelines.
For eligible patients, WHO recommends the standardized shorter (“Bangladesh”) MDR-TB
regimen of 9-11 months comprising 7 drugs in the intensive phase of 4-6 months followed by 5
months of 4 drugs in the continuation phase. This regimen was shown in a large-scale randomized
controlled study to be non-inferior to the 18-24 month WHO-recommended (2011) MDR-TB
regimen with treatment completion rates of 79.8% vs 78.8% for the long and shorter regimens
respectively.
Although WHO recommends patients with RR but isoniazid-susceptible TB be treated with MDR-
TB regimens, the evidence base for this is lacking. For rifampicin mono-resistant cases, North
American guidelines have recommended 9 -18 month regimens comprising isoniazid, ethambutol,
24
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
pyrazinamide with a fluoroquinolone, which may be augmented by an injectable agent in the initial
months of therapy for those with extensive disease.
Psychosocial and financial support to foster patient adherence, and active TB drug safety
monitoring and management (aDSM) are essential to achieve the best possible treatment outcome
for MDR-TB patients.
Extra-Pulmonary TB
Assoc Prof Tsin Wen YEO
CNS-TB
Prof Guy THWAITES
25
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
SESSION 5: UPDATE ON THE CUTTING EDGE OF TB SCIENCE
Clinical Trials in TB
Prof Nick PATON
Host-Directed Therapy in TB
Adj Asst Prof Amit SINGHAL
An effective host immune response is important to control Mycobacterium tuberculosis (Mtb) insult,
and to contain its latent persistence. A new paradigm in TB treatment, host-direct therapy (HDT),
uses adjunctive drugs to harness intrinsic antimicrobial and immunoregulatory mechanisms for better
treatment outcomes. Using chemical genetics approach we have demonstrated that activating AMP-
activated protein kinase (AMPK) and Sirtuin 1 (SIRT1), regulators of whole-body energy
metabolism, by FDA approved drugs / supplements could control inflammation and Mtb infection.
This indicates a deep engagement of Mtb pathogenicity with host’s immuno-metabolic machinery.
We hypothesize that the functional connections between immunity and pathways controlling
metabolic signaling could be harnessed to advance the host-directed therapy (HDT) pipeline,
leading to the development of clinically relevant anti-tuberculosis arsenal. We are currently
utilizing gain- and loss- of function strategies to further understand the molecular and cellular
mechanisms of AMPK and SIRT1 activators. The data related to this effort will be presented and
discussed.
New Kids on the Block
Assoc Prof Kevin PETHE
The rapid emergence and spread of multi-drug resistant Mycobacterium tuberculosis and other
pathogenic bacteria is a serious concern worldwide that advocates for the development of new
classes of antibacterials with a novel mode of action. Current antibiotics derive mainly from natural
sources and inhibit a narrow spectrum of cellular processes such as DNA replication, protein
synthesis and cell wall biosynthesis. With the spread of drug resistance, there is a renewed interest
in the investigation of alternate essential cellular processes, including central metabolic and
bioenergetics pathways, as a drug target space for the next generation of antibiotics. Oxidative
phosphorylation as recently emerged as a relevant target space for the development of new drug for
tuberculosis. In this context, I will discuss the relevance of targeting the terminal respiratory
oxidases for the development of a rational drug combination for tuberculosis and other
mycobacterial diseases.
26
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
SESSION 6: COMPLEX PATIENTS: CASE-BASED DISCUSSIONS
Tuberculosis and HIV
Prof Yee Sin LEO
Tuberculosis and Diabetes Mellitus
Prof Reinout van CREVEL
People with diabetes mellitus (DM) are an estimated 3.7 times more likely to develop TB than those
without DM, and this risk is higher with poorly controlled DM. It is estimated that DM now
accounts for >10% of TB globally, and this will increase significantly in the coming decades due to
the dramatic rise in type 2 DM in TB endemic settings.
This presentation will discuss clinical management of combined TB and DM which can be
challenging in terms of achieving good disease outcomes and avoiding toxicity, drug-interactions
etc. Diabetes management during anti-TB treatment should consist of glycaemic control and
measures to reduce the risk of cardiovascular disease. Tuberculosis treatment should be monitored
more closely, as DM is associated with an increased risk of drug-resistance, lower exposure of TB
drugs, treatment failure and recurrent TB.
Managing TB in the Immunocompromised
Asst Prof Catherine ONG
TB in immunocompromised hosts presents its own set of challenges. Rates of active TB
reactivation are higher, extra-pulmonary dissemination are more common, and treatment
complications including drug interactions are often encountered. In this talk, I shall discuss latent
TB screening and TB diagnosis in this special group of patients, illustrating with case examples,
and elaborating on treatment pitfalls to avoid.
Challenging TB Cases in Asia
Prof Guy THWAITES
27
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
SESSION 8: NON-TUBERCULOUS MYCOBACTERIA
Microbiological Diagnosis of Infections Due to Nontuberculous Mycobacteria
(NTM)
Prof Emmanuelle CAMBAU
Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies many of which can
produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites.
NTM are present in the environment and are usually nonpathogenic. Some of them are
opportunistic respiratory pathogens, causing infections that mimic tuberculosis. Some others cause
opportunistic infections observed in immunocompromised patients or as healthcare-associated
infections.NTM infections are not usually transmissible between humans and epidemic cases, but
may be linked to the same contamination event from a common reservoir. They are rare, even
though their numbers increased during the last 20 years. For respiratory cases, the diagnosis is
often fortuitous, while looking for signs of tuberculosis. Although the clinical and bacteriological
diagnoses show now a consensus, the treatment is still at the clinical research stage. Therapeutic
management is difficult also partly due to the small number of effective antibiotics, and partly
because the long-term treatment produces side effects. Mycobacterium avium complex,
Mycobacterium kansasii, Mycobacterium chelonae and Mycobacterium abscessus are the most
frequent NTM observed as opportunistic pathogens causing lung and extrarespiratory infections,
beside M. ulcerans and M. marinum that are pathogens causing specific skin and soft tissue
infections. Disseminated infections occur only in severe immunosuppressed conditions such as
AIDS or long-term corticosteroids. The diagnosis is based on repeated isolations of the same
mycobacterium associated with clinical and radiological signs, and the absence of tuberculosis or
other pathogens. Precise species identification can be obtained by molecular biology and mass
spectrometry and often requires a laboratory with NTM expertise. Therapeutic antibiotic regimens
differ with regard to the NTM species involved. Prevention of iatrogenic infections relies on using
sterile water in all injections, healthcare and cosmetic occupations. Future perspectives are to set
effective antibiotic regimens tested in randomized therapeutic trials.
An Update on the Diagnosis and Management of Non-tuberculous
Mycobacterial Infections – Perspectives from the Singapore Laboratory
Dr Li-Hwei SNG
Leprosy
Dr Chew Swee SEOW
28
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
POSTER ABSTRACTS
Clinical Profile and Outcomes of Patients with Tuberculous Arthritis Admitted
in a Tertiary Hospital in the Philippines
Poblete J1, Salamat MS2, Manapat-Reyes H3
1Department of Medicine, Philippine General Hospital 2Section of Infectious Diseases, Department of Medicine, Philippine General Hospital 3Section of Rheumatology, Department of Medicine, Philippine General Hospital
Objective: This study aims to describe the clinical profile and outcomes of patients with
tuberculous (TB) arthritis admitted in a public tertiary hospital in the Philippines.
Methodology: Clinical, laboratory, radiologic, histopathologic characteristics, and outcomes of
patients with TB arthritis admitted in the Philippine General Hospital from 2006 to 2015 were
obtained retrospectively.
Results: Among 39 patients with TB arthritis, majority were male and mean age was 50 years.
Pulmonary/disseminated TB, hypertension, diabetes, chronic kidney disease, and other
rheumatologic diseases were reported co-morbidities. A history of TB, intake of
immunosuppressive therapy, and trauma to affected joint were present in some patients. Majority
presented with chronic monoarthritis of the knees and hips with a mean diagnosis time of 18.7
months. Septic arthritis was the most frequent initial diagnosis upon consult. Anemia and elevated
Inflammatory markers (ESR and CRP) were observed in the majority. Radiographically, joint space
narrowing was common. All biopsy results showed chronic granulomatous inflammation with
caseation necrosis. All had no growth on routine bacterial culture except for one patient with
concurrent septic arthritis. All patients received standard HRZE treatment upon diagnosis. The most
common surgical interventions were debridement and arthrotomy.
Conclusion: There should be a high index of suspicion for TB arthritis in any patient from an
endemic country presenting with chronic monoarthritis in weight-bearing joints. Negative bacterial
cultures, anemia, elevated inflammatory biomarkers, and joint space narrowing on radiologic
studies could also provide potential clues in accurate diagnosis. Prompt initiation of treatment is
necessary in order to prevent significant joint destruction and disability.
29
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Comparative Genomic Analysis of Mycobacterium Tuberculosis from Pulmonary
and Central Nervous System Infections to Determine Factors of Neurotropism
Saw SH1,2, Yap SF1 and Ngeow YF1
1Department of Pre-Clinical Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku
Abdul Rahman, Malaysia 2Department of Biomedical Science, Faculty of Science, Universiti Tunku Abdul Rahman, Malaysia
Mycobacterium tuberculosis (Mtb) is the causative agent of tuberculosis (TB) and the major
mycobacterial species associated with central nervous system (CNS) infection. Tuberculous
meningitis (TBM) is a global challenge due to difficulties with diagnosis, treatment and high
mortality rate. It is not clear what factors promote CNS invasion and pathology in TB, but it has
been reported that Mtb isolates from meningitis patients show specific genetic traits not found in
respiratory isolates. Thus, in this study, genomic features of Mtb isolates from CSF and respiratory
specimens were compared to identify factors that could contribute to neurotropism in the
pathogenesis of CNS TB. First, suppression subtractive hybridisation (SSH) combined with T/A
cloning technology was utilized to build a subtracted cDNA library of genes showing DNA
sequence differences between two strains of Mtb from the CSF of Malaysian patients with
meningitis and two strains from sputum samples. Subsequently, the whole genome sequences
(WGS) of eight CSF strains from Malaysian patients presenting with TB meningitis (TBM) were
analysed against the WGS of 30 to 85 respiratory strains, including the reference strain H37Rv,
downloaded from public databases. All WGS were examined for gene rearrangements, indels,
inversions, micro-variants, as well as structural and globularity changes in proteins. In addition,
they were searched for homologs of genes previously reported to be associated with meningitis in
Mtb and three other neuropathogens, Neisseria meningitidis, Streptococcus pneumoniae and
Escherichia coli K1.
With SSH, 7 subtracted DNA fragments of various sizes were generated. With the use of BLASTN
and BLASTX, these subtracted sequences were shown to be similar to those found in Mtb strain
isolated from the brain of an Indian patient. They encode mycobacterial PE/PPE proteins which
play an important role in the evasion of host immune responses, and other conserved hypothetical
proteins with unknown function. Genome-wide comparisons revealed rearrangements
(translocations, inversions, insertions and deletions) and non-synonymous single nucleotide
polymorphisms (ns SNPs) in the CSF-derived strains that were not observed in the respiratory Mtb
genomes used for comparison. These rearranged segments were rich in genes for PE/PPE,
transcriptional and membrane proteins. Similarly, most of the ns SNPs common in CSF strains were
found in genes encoding PE/PPE proteins. Protein globularity differences were observed among
mycobacteria from both CSF and respiratory sources and in proteins previously reported to be
associated with TBM. Transcription factors and other transcription regulators featured prominently
in these proteins. Homologs of TBM-associated genes were found in the WGS of Mtb, M. bovis, M.
leprae, M. lepromatosis and two environmental non-tuberculous mycobacteria. However,
only two of these homologs were identified in all eight CSF-derived Mtb genomes. Three homologs
of 141 genes reported to be associated with S. pneumoniae meningitis and two of 164 virulence
genes reported in N. meningitidis were also found in the CSF-derived Mtb genomes. The detection
of common meningitis-associated genes in mycobacterial and non-mycobacterial neuropathogens
raises speculations on the existence of a pan-bacterial mechanism of CNS infection. However, all
the genes shared by CSF Mtb strains and other neuropathogenic bacterial spp. were also found to be
common in the comparison respiratory Mtb genomes examined. Hence, although some genetic traits
were found in CSF-derived but not sputum-derived Mtb examined in this study, there are
indications that neurotropic traits may not be specifically or universally found in Mtb causing CNS
disease. Overall, the findings from this study suggest that CNS infection in TB is more likely to be
directed by the expression of multiple virulence factors selected by the interaction between
pathogen and host immune responses, than the presence of specific genetic traits.
30
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Prevalence of Multidrug Resistant Tuberculosis and its Detection by Using
Xpert MTB/Rif Assay
Ahmad HF, Mustakim S, Gan B
Microbiology Unit, Pathology Department, Hospital Tengku Ampuan Rahimah Klang
Respiratory Unit, Department of Medicine, Hospital Tengku Ampuan Rahimah Klang
Background. Tuberculosis has still remained a major public health threat and with the emergence
of multidrug-resistant tuberculosis (MDRTB), worsened and complicates the issues. It is estimated
that in 2017, incidence rate of MDRTB in Malaysia is 1.5 per 100 000 populations with 3.1%
occurring in previously treated TB cases. The aim of our study is to know the prevalence of
MDRTB in our hospital by using Xpert MTB/Rif Assay.
Methods. A prospective study was done at Hospital Tengku Ampuan Rahimah Klang from May
2017 till May 2019. 103 smear-positive sputum samples were collected and analyzed by using
Xpert MTB/Rif Assay.
Results. Among 103 patients, 58 (56.3%) were newly diagnosed TB patients while 45 (43.7%)
were among previously treated TB patients. The median age was 39.5, ranges from 18 to 83 years
old. Males were more likely to be infected with MDRTB (62.5%) and non-MDRTB (71.6%) when
compared with females. Among all TB cases, 82.5 % were Malaysians (46.6% Malays) and only
17.5% were non-Malaysians. We detect 8 (7.8%) cases of MDRTB, in which all of them were
occurring in previously treated TB patients (p=0.008). 6 cases (75%) were treated for pulmonary
TB while the other 2 were extrapulmonary TB. 66.7 % (4 out of 6) of previously treated pulmonary
TB patients defaulted their treatment, hence pose a risk of developing MDRTB.
Conclusions. Our result demonstrated that the prevalence of MDR TB in our hospital is 7.8% with
75% occurring in previously treated pulmonary TB patients. Therefore, ensuring the adherence and
compliance to TB treatment as well as tightening follow-up strategies are crucial for better TB
control.
31
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Abdominal Cocoon Syndrome from Nontuberculous Mycobacterial Infection
Masquerading as Tuberculosis in an Incidentally-diagnosed Multiple Myeloma
Patient
Cruz MG1, Tuazon CA1, Olivar CM2, Buensalido JA1, Odoño E2, Lucero JA1, Dela Torre MK1
1Department of Medicine, Philippine General Hospital, Philippines 2Department of Laboratories, Philippine General Hospital, Philippines
Background/Aim:
Abdominal cocoon syndrome, or sclerosing encapsulating peritonitis, is a rare condition of
peritoneal fibrosis that can manifest as gut obstruction due to extrinsic bowel compression. It has
been reported in various conditions such as sarcoidosis, peritoneal dialysis, and tuberculosis.
Methods:
This paper reports the first case of abdominal cocoon syndrome caused by a rapidly-growing
nontuberculous mycobacterium, Mycobacterium fortuitum, in a 50-year old male from a high
tuberculosis burden country, the Philippines.
Results:
The patient presented at the emergency room with symptoms of gut obstruction. CT scan revealed
air-fluid level and massive fluid collection in the abdomen, suggestive of intraabdominal abscess
formation. Pigtail catheter insertion was done for diagnostic and therapeutic drainage. Culture and
sensitivity studies showed polymicrobial infection: Mycobacterium, Candida, Klebsiella, and
Citrobacter freundii – a gas-producing bacterium which may have caused the pneumoperitoneum at
the onset. Culture-guided antibiotic therapy was started. Further investigations regarding his
susceptibility to overwhelming infections led to the diagnosis of multiple myeloma. Unfortunately,
the patient succumbed to septic shock from hospital-acquired pneumonia and bacteremia. Autopsy
findings later revealed the presence of a thick fibrinous sac encasing the entire intraabdominal
viscera, suggestive of abdominal cocoon syndrome.
Conclusion:
Definitive diagnosis of abdominal cocoon syndrome is confirmed via laparotomy. Immediate
surgical intervention is warranted to provide adequate source control, and to relieve the obstruction.
The team, however, opted for conservative treatment since the patient was a poor surgical
candidate. Early diagnosis and aggressive management of infection could have been life-saving for
this case.
32
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Disseminated Mycobacterium Abscessus Infection and Multiple Myeloma in a
Patient from a Country with High Tuberculosis Burden
Villanueva CAG1, Bartolo S2, Vallente JR3, Roxas EA2
1Department of Medicine, Philippine General Hospital, University of the Philippines Manila,
Philippines 2Division of Infectious Diseases, Department of Medicine, Philippine General Hospital,
University of the Philippines Manila, Philippines 3Division of Hematology, Department of Medicine, Philippine General Hospital,
University of the Philippines Manila, Philippines
Background/Aim: There is sparse data on nontuberculous mycobacteria (NTM) infections in the
Philippines. Disseminated infection with Mycobacterium abscessus complex, which are rapidly
growing mycobacteria, is uncommon.
Methods: We discuss the clinical presentation and course of the first reported case of M. abscessus
pulmonary disease and bone marrow involvement of NTM in an HIV-negative patient from the
Philippines.
Results: A 55-year-old Filipino man presented with chronic hip pain, anemia, hypercalcemia and
acute kidney injury. He previously received an incomplete course of treatment for pulmonary
tuberculosis. A plaque with scaling on the neck was biopsied and revealed granulomatous
dermatitis. Sputum smear showed acid-fast bacilli but was negative for tuberculosis on polymerase
chain reaction. Tracheal aspirate specimens grew NTM and species identification led to M.
abscessus. Bone marrow aspirate was also positive for NTM. Osteolytic lesions on the femur were
supported by bone marrow findings suggestive of multiple myeloma. Outpatient antimycobacterial
treatment with clarithromycin, cotrimoxazole and ciprofloxacin was given based on susceptibility
testing. The patient initially received melphalan and prednisone for multiple myeloma. As of
writing, the patient was on the ninth month of treatment and was recently hospitalized due to
symptomatic anemia. Repeat sputum smears were negative for acid-fast bacilli.
Conclusion: Even in areas of high tuberculosis burden, clinicians should consider NTM in the
differential diagnoses of patients with chronic respiratory symptoms and cutaneous infections
especially in the setting of immunocompromising conditions like hematologic malignancies.
33
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
The Cascade of Care of Rifampicin-Resistant Tuberculosis: Experience from a
Tertiary Hospital in Bandung, Indonesia
Larasmanah ASN1, Lestari BW1,2,3, Santoso P4, Soeroto AY4, van Crevel R3,5, Hill PC6
1Infectious Disease Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung,
Indonesia 2Department of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia3Department of Internal Medicine, Radboud Institute for Health Sciences, Radboud University
Medical Center, Nijmegen, The Netherlands 4Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan
Sadikin General Hospital, Bandung, Indonesia 5Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of
Oxford, Oxford, United Kingdom 6Center for International Health, University of Otago, Dunedin, New Zealand
Background:
The emergence of rifampicin-resistant TB (RR-TB) is threat for TB control program in Indonesia.
The TB cascade of care is useful to identify where patients are lost or have sub-optimal
management from initial screening to the end of treatment. We aimed to describe the cascade of
care for newly diagnosed RR-TB, including characterising a ‘secondary cascade’ in those without
phenotypic drug-susceptibility testing (DST) results at the time of treatment initiation.
Methods:
We analysed a cohort of RR-TB patients registered in Hasan Sadikin Hospital over period of 2015-
2016. We identified the following cascade steps for newly diagnosed RR-TB patients: 1) the
number of presumptive RR-TB; 2) RR-TB confirmed by GenXpert; 3) RR-TB with initial
assessment; 4) RR-TB starting second-line treatment; and 5) successfully treated RR-TB. We
compiled a secondary cascade after step 2, for patients starting treatment without available DST
result.
Results
Of 3415 patients registered as presumptive RR-TB , 3215 (94%) were tested by GenXpert, of whom
376 (11.7%) were diagnosed as RR-TB. 333/376 (89%) were newly diagnosed while 43 had
received RR-TB treatment previously. 283/333 (85%) initiated treatment, 143/333 (43%) were
confirmed as MDR-TB through DST, 190 had no DST result available. The treatment success rate
was 89/140 (64%; 27% of all newly diagnosed) for those with baseline phenotypic DST results who
commenced treatment, compared to 76/143 (53%) in those without DST confirmation (p value =
0.05).
Conclusion
Only 27% of RR-TB patients successfully progressed through a full ‘primary’ cascade of care.
Baseline phenotypic DST is important for the best treatment outcome.
34
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Matrix Metalloproteinase (MMP) Inhibitor Doxycycline Suppresses Systemic
and Respiratory MMPs in Patients with Pulmonary TB
Miow QH1, Wang Y1, Teo F2, Wang DA2, Loh HR1, Hong JM1, Tan TZ3, Ding Y4, Gan SH5, She
HW5, Paton NI1, Singhal A6, Tambyah PA1,2, Chee C5, Wang YT5, Elkington PT7, Friedland JS8,
Ong CWM1,2,5
1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore,
Singapore 2Division of Infectious Diseases, National University Health System, Singapore 3Cancer Science Institute of Singapore, National University of Singapore, Singapore 4Clinical Services, National Centre for Infectious Diseases, Singapore 5Tuberculosis Control Unit, Tan Tock Seng Hospital, Singapore 6Singapore Immunology Network, A*Star, Singapore 7Medicine, University of Southampton, United Kingdom 8Institute of Infection and Immunity, St George’s, University of London, United Kingdom
Background/Aim: Tuberculosis (TB) causes tissue destruction where the activity of matrix
metalloproteinases (MMPs) are unopposed to tissue inhibitors (TIMPs). We hypothesize that
doxycycline, a licensed MMP inhibitor, decreases matrix degradation in TB patients.
Methods: 30 HIV-negative pulmonary TB patients were randomized to 14 days of doxycycline or
placebo in addition to standard anti-TB treatment. Subjects were followed-up at days 14, 28 and 56.
Clinical data, sputum and blood were collected. Primary endpoint was change in N-terminal pro-
peptide of Type III collagen (PIIINP) from day 0 to day 14. Secondary endpoints were change of
sputum M. tuberculosis (Mtb) colony forming units (cfu), chest radiograph (CXR), MMPs, TIMPs,
as well as Type I collagen and elastin degradation activities. PIIINP, MMPs and degradation
activities were assessed by ELISA, luminex array and quantitative fluorometry, respectively.
Results: Median age of TB patients was 47.5 years old and 20% were women. 66% of TB patients
had grade 1 and 2 adverse events which were mainly nausea and vomiting. None experienced
serious adverse events. Plasma PIIINP increased at day 14 with doxycycline (p < 0.05). Sputum
MMP-1, -8, -9, -12 and -13 decreased with doxycycline at day 14, with concomitant decrease in
sputum Type I collagen and elastin degradation activities (all p < 0.05). Plasma MMP-1 and -8
were also decreased with doxycycline (all p < 0.05). CXR, pulmonary cavities and sputum Mtb cfu
were unchanged between groups.
Conclusion: 2 weeks of adjunctive doxycycline is safe with standard anti-TB treatment and
resulted in sputum and systemic MMPs suppression in TB patients.
35
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
Low Uptake of Window Prophylaxis in High Risk Children After Exposure to
Pulmonary Tuberculosis from a Healthcare Worker
Sinnathamby A1, Ang SBN1, Bagdasarian N2,3,4, Chan HC3, Chan SM1,3
1Department of Paediatrics, Khoo Teck Puat National University Children’s Medical Institute,
National University Hospital, Singapore 2National University Hospital, Department of Medicine, Division of Infectious Diseases, Singapore 3Yong Loo Lin School of Medicine, National University of Singapore, Singapore 4Department of Infection Prevention, National University Hospital, Singapore
Background: A nurse caring for paediatric inpatients was diagnosed with smear positive
pulmonary TB after 5 months of cough. 173 children (<2 years old, immunocompromised or >40
hours of contact) were contact traced.
Methods: Children received clinical review, chest X-ray, and a tuberculin skin test (TST) (<5 years
old) and/or an interferon gamma release assay (Quantiferon TB-Gold) (>5 years old). Infants <6
months old and children screened <2 months from time of exposure were recommended isoniazid
window prophylaxis (WP) until a repeat TST at 6 months old or 8-10 weeks later respectively.
Empiric treatment of 9 months isoniazid for latent tuberculosis infection (LTBI) was considered for
immunocompromised patients on an individual basis. Patient information leaflets and counselling
were provided.
Results: 126 immunocompetent and 36 immunocompromised children were screened. 2 were
uncontactable, 7 refused screening. 2 immunocompromised children were excluded. 8
immunocompetent children were diagnosed with LTBI (initial TST positive n=7, TST conversion
n=1); 7 (88%) accepted LTBI treatment. 15 (47%) of 32 immunocompetent children accepted the
recommended WP; 1 was non-compliant after 1 month.
6 (86%) of 7 immunocompromised children accepted recommended empiric LTBI treatment due to
severe immunosuppression (n=5) or initial indeterminate Quantiferon TB-Gold result (n=2). 5 (33%)
of 15 immunocompromised children accepted the recommended WP; 1 developed rash and
discontinued isoniazid after 2 weeks.
Conclusion: There was low uptake of isoniazid WP in high risk children exposed to pulmonary TB.
Perception of exposure risk and reluctance to take medication with potential adverse effects should
be explored further.
36
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
MMP-2 and -9 are Increased in Paediatric Tuberculous Meningitis (TBM)
Patients and a Murine Central Nervous System Tuberculosis (CNS-TB) Model
Poh XY1, Hong JM1, Miow QH1, Yeo TW2, Ong CWM1
1Department of Medicine, National University of Singapore, Singapore 2Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
Background/Aim: CNS-TB patients develop extensive brain inflammation and tissue destruction,
characterised by a matrix-degrading phenotype. 45% patients also develop strokes. However, the
mechanisms underlying inflammation, tissue destruction and strokes remain undefined.
Methods: The cerebrospinal fluid (CSF) of 62 paediatric patients with tuberculous (TBM),
bacterial (BM), viral (VM) and non-infectious meningitis were analysed for matrix
metalloproteinases (MMPs) by luminex array and neutrophil extracellular traps (NETs) by
quantitative fluorometry. To develop a murine CNS-TB model, mouse strains Nos2-/- and
C3HeB/FeJ, Mycobacterium tuberculosis (M.tb) strains H37Rv and CDC1551 and routes of
infection by intra-cerebroventricular (ICV) and intravenous (IV) were evaluated. Murine expression
levels of MMPs, tissue-specific inhibitors of metalloproteinases (TIMPs), adhesion molecules,
cytokines and chemokines in the brain were analysed by luminex array.
Results: CSF EMMPRIN, MMP-2 and -9 concentrations were significantly increased in TBM
patients compared to BM patients. CSF extracellular DNA concentration was increased in TBM
patients compared to non-infectious and VM patients, showing a significant negative correlation
with clinical neurological scores. Nos2-/- mice developed myoclonic jerks, seizures and limb
weakness from 3 weeks post-infection while C3HeB/FeJ remained normal. Murine brain MMP-2
and -9 concentrations in infected Nos2-/- mice were increased relative to saline controls. Nos2-/-
mice infected with CDC1551 strain via the ICV route had a significantly higher mortality (100%
mortality by 42 days post-infection) compared to the IV route (0% mortality).
Conclusion: The increase in MMP-2 and -9 concentrations is found both in humans and in our
murine model, and may drive CNS-TB immunopathology.
37
ESCMID Postgraduate Education Course
Tuberculosis and Mycobacterial Infections: An Educational Update
ACKNOWLEDGEMENTS
The Organising Committee would like to thank the following for their kind and
generous contributions for the course:
SUPPORTING ORGANISATIONS
SPONSORS